Canopy Growth (CGC) Accounts Payables (2017 - 2026)
Canopy Growth (CGC) reported Accounts Payables of $25.4 million for Q1 2026, up 39.58% on a YoY basis from $18.2 million in Q1 2025, and up 77.36% sequentially from $14.3 million in Q4 2025.
Canopy Growth (CGC) Accounts Payables (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Accounts Payables data on file, last reported at $25.4 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 39.58% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (up 39.58% YoY), and the FY2026 full-year result was $25.4 million, up 39.58% from the prior year.
- Accounts Payables rose to $25.4 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $52.3 million in Q3 2022 to a low of $13.2 million in Q3 2025.
- A 5-year average of $27.4 million and a median of $20.7 million in 2024 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables plunged 67.59% in 2023 and surged 39.58% in 2026, its largest moves.
- Tracing CGC's Accounts Payables over 5 years: stood at $46.5 million in 2022, then slumped by 59.2% to $19.0 million in 2023, then increased by 9.08% to $20.7 million in 2024, then sank by 30.85% to $14.3 million in 2025, then soared by 77.36% to $25.4 million in 2026.
- Business Quant data shows CGC's Accounts Payables at $25.4 million in Q1 2026, $14.3 million in Q4 2025, and $13.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 25.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.39 Mn |
| Dec 31, 2025 | 14.32 Mn |
| Sep 30, 2025 | 13.18 Mn |
| Jun 30, 2025 | 17.38 Mn |
| Mar 31, 2025 | 18.19 Mn |
| Dec 31, 2024 | 20.70 Mn |
| Sep 30, 2024 | 13.46 Mn |
| Jun 30, 2024 | 18.64 Mn |
| Mar 31, 2024 | 21.28 Mn |
| Dec 31, 2023 | 18.98 Mn |
| Sep 30, 2023 | 16.95 Mn |
| Jun 30, 2023 | 42.85 Mn |
| Mar 31, 2023 | 23.55 Mn |
| Dec 31, 2022 | 46.51 Mn |
| Sep 30, 2022 | 52.29 Mn |
| Jun 30, 2022 | 50.71 Mn |
| Mar 31, 2022 | 50.74 Mn |
| Dec 31, 2021 | 53.82 Mn |
| Sep 30, 2021 | 74.97 Mn |
| Jun 30, 2021 | 74.31 Mn |